ADPT Stock Down -15% after 7-Day Loss Streak
Adaptive Biotechnologies (ADPT) stock hit day 7 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -15% return. The company has lost about $225 Mil in value over the last 7 days, with its current market capitalization at about $1.5 Bil. The stock remains 72.0% above its value at the end of 2024. This compares with year-to-date returns of 7.2% for the S&P 500.
Comparing ADPT Stock Returns With The S&P 500
The following table summarizes the return for ADPT stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ADPT | S&P 500 |
|---|---|---|
| 1D | -0.8% | 0.1% |
| 7D (Current Streak) | -14.7% | 0.4% |
| 1M (21D) | -1.5% | 5.4% |
| 3M (63D) | 40.7% | 19.4% |
| YTD 2025 | 72.0% | 7.2% |
| 2024 | 22.3% | 23.3% |
| 2023 | -35.9% | 24.2% |
| 2022 | -72.8% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 80 S&P constituents with 3 days or more of consecutive gains and 30 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 27 | 23 |
| 4D | 48 | 0 |
| 5D | 0 | 3 |
| 6D | 3 | 0 |
| 7D or more | 2 | 4 |
| Total >=3 D | 80 | 30 |
Key Financials for Adaptive Biotechnologies (ADPT)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $170.3 Mil | $179.0 Mil |
| Operating Income | $-201.6 Mil | $-155.3 Mil |
| Net Income | $-225.2 Mil | $-159.5 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $47.5 Mil | $52.4 Mil |
| Operating Income | $-33.8 Mil | $-29.6 Mil |
| Net Income | $-33.7 Mil | $-29.9 Mil |
The losing streak ADPT stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.